Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d6893b2c8f994bcf1f2eb3 — DOI: https://doi.org/10.1056/nejmoa1716153

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas· 2012 · 204 citations
2. Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)· 2015 · 12 citations
3. Progression of transthyretin amyloid neuropathy after liver transplantation· 2010 · 154 citations
4. Cardiac transthyretin amyloidosis· 2012 · 135 citations
5. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)· 2012 · 256 citations